ERBB2 and gastric cancer: HER2-targeted therapy with monoclonal antibodies (mAbs) is a promising strategy for the ovarian carcinoma, although trastuzumab (trademark: herceptin, Genetech, Roche) has not got such great success in ovarian carcinoma as in breast or gastric cancer [6,7].